hsa-mir-1469: Hsa-mir-1469 is one of the nine miRNAs that were significantly upregulated by ACBP-3 and selected for further analysis [PMC5034486]. Hsa-mir-1469 has been associated with the overall survival of patients with pancreatic ductal adenocarcinoma (PDAC) [PMC8613738]. It has also been shown to induce apoptosis in cancer cells [PMC9221798]. Hsa-mir-1469, along with hsa-miR-133a-5p and hsa-miR-10b-5p, may play important roles in the protective effect of icariin against glucocorticoid-induced injury [PMC9221798]. The expression of hsa-mir-1469 was found to be downregulated in resting samples from various cell types compared to HIV-negative samples [PMC4865051]. Hsa-mir-1469 has also been implicated in the regulation of PRAS40 levels and cancer cell migration and invasion [PMC9389164]. It is upregulated by ATF4 signals and leucine deprivation, suggesting its involvement in cellular stress responses [PMC9389164]. Hsa-mir-1469 may serve as a potential biomarker for thyroid disorders (TDs) diagnosis, as its expression was found to be downregulated in plasma samples from patients with TDs compared to healthy controls [PMC9312839]. Additionally, hsa-mir-1469 has been associated with pancreatic cancer prognosis and primary resistance to EGFR-TKI treatment [PMC8809919] [PMC5687624]. The expression of hsa-miR-3960, hsa-miR-4497, hsa-miR-3665, hsa-miR4787–5p, miR17 and miR221/222 miRNA clusters was comparatively high compared to other miRNAs [PMC5029934]. Hsa-mir-1469 has a high GC content [PMC2774487].